More than 160 authors—including more than 75 new contributors—lent their expertise to this sixth edition of The American Psychiatric Association Publishing Textbook of Psychopharmacology. Featuring 12 all-new chapters and fully aligned with the revised DSM-5-TR classification, this two-volume text offers an unrivaled, in-depth look at the rapidly evolving field of neuropsychopharmacology.
The opening chapters provide a whirlwind tour of the multiple disciplines that undergird the chapters to come, with topics extending from the principles of molecular biology and genomics to the rudiments of neuroimaging and personalized medicine in psychiatry. The main body of the Textbook features an examination of the medication classes that form the basis of psychopharmacological treatment. For each drug within a class, data are reviewed on history and discovery, preclinical and clinical pharmacology, pharmacokinetic parameters, mechanism of action, indications and efficacy, side effects and toxicology, and drug-drug interactions. The Textbook’s second volume focuses on psychopharmacological approaches to treatment of patients with major psychiatric disorders (e.g., mood and anxiety disorders, schizophrenia, substance use disorders) as well as patients in specific populations (e.g., adults with ADHD, pediatric patients). For each specific condition, patient population, or setting, chapters provide guidance on topics such as medication selection, combination and maintenance dosing regimens, side-effect monitoring and management, and optimization of treatment response. Closing this volume is an Appendix of Psychiatric Medications with key information on each of the agents covered in the Textbook, presented in a convenient tabular format.
Noteworthy additions to this textbook include chapters addressing the following topics:
• The potential roles of personalized medicine in psychiatry and of artificial intelligence and machine learning in psychopharmacology• New medications with novel pharmacological mechanisms, including the neurosteroid antidepressant brexanolone and the atypical antipsychotic pimavanserin• Use of investigational agents, such as psychedelics, in psychiatric treatment• Treatment of alcohol use disorder, PTSD, OCD, and autism spectrum disorder• Treatment of ADHD in adults• Treatment of women in all life phases, including during pregnancy and the postpartum period• Treatment of individuals with intellectual developmental disorder
With a level of detail not found in any other source, this new edition of The American Psychiatric Association Publishing Textbook of Psychopharmacology illuminates the path to effective evidence-based practice of psychopharmacology for novice and seasoned clinicians alike.
Inhoudsopgave
Contents Contributors Introduction PART I Principles of Pharmacology Chapter 1. Basic Principles of Molecular Biology and Genomics Chapter 2. Neurotransmitters, Receptors, and Transporters Chapter 3. Genetics and Epigenetics Chapter 4. Psychoneuroendocrinology Chapter 5. Brain–Immune System Interactions Chapter 6. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics Chapter 7. Neuroimaging and Psychiatry Chapter 8. Personalized Medicine in Psychiatry Chapter 9. Machine Learning in Psychopharmacology Chapter 10. Monoamine Oxidase Inhibitors.Chapter 11. Tricyclic and Tetracyclic Drugs Chapter 12. Fluoxetine and Fluvoxamine Chapter 13. Sertraline and Paroxetine Chapter 14. Citalopram and Escitalopram Chapter 15. Trazodone and Nefazodone Chapter 16. Vortioxetine Chapter 17. Mirtazapine Chapter 18. Bupropion Chapter 19. Venlafaxine and Desvenlafaxine Chapter 20. Duloxetine, Milnacipran, and Levomilnacipran Chapter 21. Ketamine and Esketamine Chapter 22. Benzodiazepines Chapter 23. Buspirone Chapter 24. Brexanolone and Other Neurosteroids Chapter 25. Classic Antipsychotic Medications Chapter 26. Clozapine Chapter 27. Olanzapine Chapter 28. Quetiapine Chapter 29. Risperidone and Paliperidone Chapter 30. Aripiprazole and Brexpiprazole Chapter 31. Ziprasidone and Asenapine Chapter 32. Iloperidone Chapter 33. Lurasidone Chapter 34. Cariprazine Chapter 35. Pimavanserin Chapter 36. Management of Psychiatric Medication–Induced Movement Disorders Chapter 37. Lithium Chapter 38. Valproate Chapter 39. Carbamazepine, Oxcarbazepine, and Licarbazepine Chapter 40. Gabapentin and Pregabalin Chapter 41. Lamotrigine Chapter 42. Topiramate Chapter 43. Agents for Cognitive Disorders Chapter 44. Sedative-Hypnotics Chapter 45. Psychostimulants and Wakefulness-Promoting Agents Chapter 46. Electroconvulsive Therapy and Other Neuromodulation Therapies Chapter 47. Psychedelic Drugs as Treatments in Psychiatry PART III Psychopharmacological Treatment Chapter 48. Treatment of Depression Chapter 49. Treatment of Bipolar Disorder Chapter 50. Treatment of Anxiety and Related Disorders Chapter 51. Treatment of Posttraumatic Stress Disorder Chapter 52. Treatment of Obsessive-Compulsive Disorder Chapter 53. Treatment of Schizophrenia Chapter 54. Treatment of Substance Use Disorders Chapter 55. Treatment of Alcohol Use Disorder Chapter 56. Treatment of Personality Disorders Chapter 57. Treatment of Eating Disorders Chapter 58. Treatment of Insomnia Chapter 59. Treatment of Chronic Pain Chapter 60. Treatment of Child and Adolescent Disorders Chapter 61. Treatment During Late Life Chapter 62. Treatment of Women Excluding Pregnancy and Postpartum Chapter 63. Treatment of Women During Pregnancy and Lactation Chapter 64. Treatment of Attention-Deficit/Hyperactivity Disorder in Adults Chapter 65. Treatment of Individuals With Intellectual Developmental Disorder Chapter 66. Treatment of Autism Spectrum Disorder Chapter 67. Treatment of Psychiatric Emergencies.Appendix Psychiatric Medications Index
Over de auteur
Alan F. Schatzberg, M.D., is Kenneth T. Norris Jr. Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine in Stanford, California, where from 1991 to 2010 he was also Chair of Psychiatry. He is currently Director of the Stanford Mood Disorders Center.
Charles B. Nemeroff, M.D., Ph.D., is Matthew P. Nemeroff Professor and Chair of the Department of Psychiatry and Behavioral Sciences, Mulva Clinic for the Neurosciences; Director of the Institute of Early Life Adversity Research; and Co-Director of the Center for Psychedelic Research and Therapy at the Dell Medical School of The University of Texas at Austin.
Meer e-boeken van dezelfde auteur (s) / Editor
144.005 E-boeken in deze categorie
